STO · H100.ST
H100 Group AB
SEK 2.03+SEK 0.08 (+3.89%)
H100 Group AB: Technology · Software - Application.
Loading market information…
XETRA · 93M1.DE · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
MPH Health Care AG’s quoted price sits in the upper half of its reported 52-week range, 4.38% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
MPH Health Care AG’s forward annual dividend is €5.00 per share, paid annual. The forward yield is 17.61% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
MPH Health Care AG’s next earnings report is currently expected on Apr 29, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow MPH Health Care AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MPH Health Care AG is a German-based investment firm with a primary focus on the healthcare sector. The company's portfolio includes the production and distribution of medicinal products designed to treat serious illnesses like cancer, HIV, and various other chronic conditions. Beyond pharmaceuticals, it also delivers medical aesthetic treatments, develops and markets a diverse array of pharmaceutical and medical items, and furnishes related services and specialized medical devices for use in aesthetic surgery and cosmetic dermatology. Furthermore, its operations extend to supplying cytostatic solutions and involvement in real estate ventures. Established in Berlin in 2008, the company adopted its current name, MPH Health Care AG, in 2017, having previously been known as MPH Mittelständische Pharma Holding AG. It functions as a subsidiary of Magnum AG.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:18 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 2.03+SEK 0.08 (+3.89%)
H100 Group AB: Technology · Software - Application.
€525.00+€5.00 (+0.96%)
LIMES Schlosskliniken AG’s quoted price sits in the upper half of its reported 52-week range, 11.76% below the high.
€11.00€0.00 (0.0%)
Apontis Pharma AG’s quoted price sits in the lower half of its reported 52-week range, 10.93% below the high.
€2.78+€0.22 (+8.59%)
BRAIN Biotech AG’s quoted price sits in the lower half of its reported 52-week range, 28.53% below the high.
€10.50€0.00 (0.0%)
DocCheck AG’s quoted price sits in the lower half of its reported 52-week range, 33.96% below the high.
€2.79€0.00 (0.0%)
FamiCord AG’s quoted price sits in the lower half of its reported 52-week range, 60.98% below the high.
€20.20+€0.20 (+1.0%)
MeVis Medical Solutions AG’s quoted price sits in the lower half of its reported 52-week range, 24.63% below the high.
€1.64+€0.06 (+3.81%)
NanoRepro AG’s quoted price sits in the lower half of its reported 52-week range, 31.88% below the high.
